Short-term treatment with AZD4573 led to a rapid dose- and time-dependent decrease in cellular pSer2-RNAPII, resulting in activation of caspase 3 and cell apoptosis in a broad range of hematological cancer cell lines (e.g. caspase activation EC50 13.7 nM in an acute myeloid leukemia model MV4-11).

AZD4573 exhibits a short half-life in multiple species (less than one hour in dog, rat, and monkey) and good solubility for intravenous administration.